Emergent Biosolutions Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
50.02 M |
Public Float |
42.07 M |
Emergent Biosolutions Inc. | |
Stock Exchange | New York Stock Exchange |
EPS |
$0.81 |
Market Cap |
$2.34 B |
Shares Outstanding |
51.4 M |
Public Float |
42.67 M |
Address |
400 Professional Drive Gaithersburg Maryland 20879 United States |
Employees | - |
Website | http://www.emergentbiosolutions.com |
Updated | 07/08/2019 |
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures that address public health and national security threats. It includes Chemical, Biological, Radiological, Nuclear and Explosive or CBRNE threats; as well as emerging infectious diseases. Its business units include Vaccines and Anti-Infectives; Antibody Therapeutics; Devices; and Contract Development and Manufacturing. |